

Clinical trials of dipyridamol

TrialResults-center www.trialresultscenter.org

1 post myocardial infarction

Trial	Treatments	Patients	Trials design and methods
dipyridamol + aspirin vs placebo			
PARIS , 1980 n=810/406 follow-up: 41 months (mean)	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and UK
PARIS-II , 1986 n=1563/1565 follow-up: 23.4 months	Aspirin (330 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously	Parallel groups Double blind USA and UK
dipyridamol + aspirin vs aspirin			
PARIS , 1980 n=810/810 follow-up: 41 months	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Aspirin (324 mg) 3x/d	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and GB

More details and results :

- antiplatelets drug for post myocardial infarction in all type of patient at <http://www.trialresultscenter.org/go-Q277>
- secondary prevention for post myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q449>

References

PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

PARIS-II, 1986:

Klimt CR, Knatterud GL, Stamler J, Meier P, Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7:251-69 [2868029]

PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

2 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
dipyridamol vs control			
Atlanta (Sbar) , 1967 n=30/30 follow-up: 6 months	dipyridamole 150mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Wirecki , 1967 n=28/28 follow-up: 7 months	dipyridamole 150mg daily versus placebo	patients with angina pectoris	parallel groups double blind
Becker , 1967 n=14/13 follow-up: 5 months	dipyridamole 225mg daily versus placebo	-	parallel groups double-blind
aspirin + dipyridamol vs placebo			
Hess (2) , 1985 n=80/80 follow-up:	Aspirine Dipyridamole 330 mg / j 225 mg / j versus Placebo	patients with occlusive arterial disease in the lower extremities	Parallel groups double blind
Schoop (2) , 1983 n=100/100 follow-up:	Aspirine Dipyridamole 990 mg / j 225 mg /j versus Placebo	AOMI stade non prcis	Parallel groups double blind
VA study , 1986 n=110/121 follow-up: 46 months	Aspirine + Dipyridamole 975 mg / j 225 mg /j versus Placebo	non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene	Parallel groups double blind
dipyridamol vs placebo			
Kinsella , 1962 n=13/13 follow-up: 0.5 months	dipyridamole 37.5 mg and 100mg daily versus placebo	-	parallel groups double-blind
Leiberman , 1964 n=19/19 follow-up: >3 months	dipyridamole 100mg daily versus placebo	-	parallel groups double blind
Zion , 1961 n=14/14 follow-up: 0.5 months	Dipyridamole 37.5mg versus placebo	patients with angina pectoris	cross-over double-blind
Dewar , 1961 n=17/17 follow-up: 0.5 months	Dipyridamole 100mg daily versus placebo	patients with angina pectoris	parallel groups double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
Neumann , 1964 n=20/16 follow-up: 1.5 months	dipyridamole 150mg daily versus placebo	elderly with precordial pain	parallel groups double-blind
Foulds , 1960 n=24/24 follow-up: 1 months	Dipyridamole 200mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Igloe , 1970 n=26/22 follow-up: 2-7 months	Dipyridamole 200mg daily versus placebo	patients with angina pectoris	parallel groups double blind
dipyridamol + aspirin vs placebo			
PARIS , 1980 n=810/406 follow-up: 41 months (mean)	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and UK
PARIS-II , 1986 n=1563/1565 follow-up: 23.4 months	Aspirin (330 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously	Parallel groups Double blind USA and UK
dipyridamol + aspirin vs aspirin			
PARIS , 1980 n=810/810 follow-up: 41 months	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Aspirin (324 mg) 3x/d	patuents who had recovered from myocardial infarction	Parallel groups Double blind USA and GB

More details and results :

- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication at <http://www.trialresultscenter.org/go-Q275>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with CAD at <http://www.trialresultscenter.org/go-Q276>

References

Atlanta (Sbar), 1967:

Sbar S, Schlant RC Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA 1967;201:865-7 [5340622]

Wirecki, 1967:

Wirecki M Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis 1967;20:139-45 [5336520]

Becker, 1967:

Becker MC. Angina pectoris: A double blind study with dipyridamole Journal of the Newark Beth Israel Hospital 1967;18:88-94

Hess (2), 1985:

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Hess H, Mietaschk A, Deichsel G Lancet 1985 Feb 23;1:415-9 [2857803]

Schoop (2), 1983:

W Schoop, H Levy. prevention of peripheral arterial occlusive disease with antiaggregants. Thromb Haemost 1983, 30: 137.

VA study, 1986:

Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Colwell JA, Bingham SF, Abaira C, Anderson JW, Comstock JP, Kwaan HC, Nuttall F Diabetes Care 1986 Mar-Apr;9:140-8 [3516608]

Kinsella, 1962:

KINSELLA D, TROUP W, MCGREGOR M Studies with a new coronary vasodilator drug: persantin. Am Heart J 1962;63:146-51 [14456202]

Leiberman, 1964:

LEIBERMAN A, GUGLIELMELLI S PERSANTIN- A DOUBLE BLIND STUDY. Angiology 1964;15:290-2 [14170587]

Zion, 1961:

ZION MM, BRADLOW BA A controlled clinical trial of 'persantin' (R A 8) in angina pectoris. S Afr Med J 1961;35:11-3 [13788617]

Dewar, 1961:

DEWAR HA, HORLER AR A clinical trial of Persantin and Crodimyl in the treatment of angina of effort. Scott Med J 1961;6:149-52 [13722387]

Neumann, 1964:

NEUMANN M, LUISADA AA EFFECT OF RAPID AND SLOW-ACTING "CORONARY" DRUGS ON PRECORDIAL PAIN OF THE AGED. Am J Med Sci 1964;247:156-63 [14124704]

Foulds, 1960:

FOULDS T, MACKINNON J Controlled double-blind trial of "persantin" in treatment of angina pectoris. Br Med J 1960;2:835 [13824151]

Igloe, 1970:

Igloe MC Treatment of angina pectoris with dipyridamole: a double-blind study. J Am Geriatr Soc 1970;18:233-41 [4984849]

PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

PARIS-II, 1986:

Klimt CR, Knatterud GL, Stamler J, Meier P, Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7:251-69 [2868029]

PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

3 stable angina

Trial	Treatments	Patients	Trials design and methods
dipyridamol vs control			
Atlanta (Sbar) , 1967 n=30/30 follow-up: 6 months	dipyridamole 150mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Wirecki , 1967 n=28/28 follow-up: 7 months	dipyridamole 150mg daily versus placebo	patients with angina pectoris	parallel groups double blind
Becker , 1967 n=14/13 follow-up: 5 months	dipyridamole 225mg daily versus placebo	-	parallel groups double-blind
dipyridamol vs placebo			
Kinsella , 1962 n=13/13 follow-up: 0.5 months	dipyridamole 37.5 mg and 100mg daily versus placebo	-	parallel groups double-blind
Leiberman , 1964 n=19/19 follow-up: >3 months	dipyridamole 100mg daily versus placebo	-	parallel groups double blind
Zion , 1961 n=14/14 follow-up: 0.5 months	Dipyridamole 37.5mg versus placebo	patients with angina pectoris	cross-over double-blind
Dewar , 1961 n=17/17 follow-up: 0.5 months	Dipyridamole 100mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Neumann , 1964 n=20/16 follow-up: 1.5 months	dipyridamole 150mg daily versus placebo	elderly with precordial pain	parallel groups double-blind
Foulds , 1960 n=24/24 follow-up: 1 months	Dipyridamole 200mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Igloe , 1970 n=26/22 follow-up: 2-7 months	Dipyridamole 200mg daily versus placebo	patients with angina pectoris	parallel groups double blind

More details and results :

- antithrombotics for stable angina in all type of patient at <http://www.trialresultscenter.org/go-Q33>

References

Atlanta (Sbar), 1967:

Sbar S, Schlant RC Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA 1967;201:865-7 [5340622]

Wirecki, 1967:

Wirecki M Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis 1967;20:139-45 [5336520]

Becker, 1967:

Becker MC. Angina pectoris: A double blind study with dipyridamole Journal of the Newark Beth Israel Hospital 1967;18:88-94

Kinsella, 1962:

KINSELLA D, TROUP W, MCGREGOR M Studies with a new coronary vasodilator drug: persantin. Am Heart J 1962;63:146-51 [14456202]

Leiberman, 1964:

LEIBERMAN A, GUGLIELMELLI S PERSANTIN- A DOUBLE BLIND STUDY. Angiology 1964;15:290-2 [14170587]

Zion, 1961:

ZION MM, BRADLOW BA A controlled clinical trial of 'persantin' (R A 8) in angina pectoris. S Afr Med J 1961;35:11-3 [13788617]

Dewar, 1961:

DEWAR HA, HORLER AR A clinical trial of Persantin and Crodimyl in the treatment of angina of effort. Scott Med J 1961;6:149-52 [13722387]

Neumann, 1964:

NEUMANN M, LUISADA AA EFFECT OF RAPID AND SLOW-ACTING "CORONARY" DRUGS ON PRECORDIAL PAIN OF THE AGED. Am J Med Sci 1964;247:156-63 [14124704]

Foulds, 1960:

FOULDS T, MACKINNON J Controlled double-blind trial of "persantin" in treatment of angina pectoris. Br Med J 1960;2:835 [13824151]

Igloe, 1970:

Igloe MC Treatment of angina pectoris with dipyridamole: a double-blind study. J Am Geriatr Soc 1970;18:233-41 [4984849]

4 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
aspirin + dipyridamol vs placebo			
Prandoni , 1991 n=44/44 follow-up: 12m	Aspirin 50mg/d + Dipyridamol 400mg/d versus placebo	patients with acute unstable angina	double blind

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- antiplatelets drug for acute coronary syndrome in ACS (excluding AMI) at <http://www.trialresultscenter.org/go-Q169>
- antiplatelets drug for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q346>

References

Prandoni, 1991:

Prandoni P, Milani L, Barbiero M, Cardaioli P, Sanson A, Barbaresi F, Zonzin P, Visani L [Treatment of unstable angina with dipyridamole combined with low doses of aspirin. A multicenter pilot double-blind controlled study] *Minerva Cardioangiol* 1991;39:267-73 [[1780077](#)]

5 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
aspirin + dipyridamol vs control			
Chicago , 1982 n=12/15 follow-up:	aspirin, 300 mg bid, and dipyridamole, 75 mg tid versus control	patients with acute spinal cord injury	Parallel groups open
dipyridamol + aspirin vs control			
Parodi I , 1973 n=40/22	Dip,A1000+Dip versus control	-	open
Parodi II , 1973 n=91/35	A1500,Dip,A+Dip versus control	-	open
Australian I , 1975 n=75/75	A1000+Dip versus control	-	open
Australian II , 1976 n=85/75	A1000+Dip versus control	-	open
Toulouse I , 1979 n=38/66	A990+Dip versus control	-	open
Zekert-III , 1977 n=135/46	A1500,A1300+Dip,A1000+Dip versus control	-	open
Harjola DVT , 1982 n=300/100	A1500,Dip,A+Dip versus control	-	open

continued...

Trial	Treatments	Patients	Trials design and methods
Weiss , 1977 n=30/36	A990+Dip versus control	-	open
aspirin + dipyridamol vs no treatment			
Morris-B , 1977 n=32/32 follow-up:	Aspirin 900 mg daily + dipyridamole versus control	elderly patients with hip fractures	Parallel groups open
Lyon-I , 1975 n=20/20 follow-up: 2 weeks	Aspirin 1500 mg daily + Dipyridamole versus control	Elective orthopaedic surgery	
dipyridamol vs no treatment			
Morris-A , 1977 n=24/24 follow-up:	dipyridamole versus control	elderly patients with hip fractures	Parallel groups open
aspirin + dipyridamol vs placebo			
Encke-II , 1976 n=34/25 follow-up:	Aspirin 1500mg daily, Aspirin 990mg daily + dipyridamol versus placebo	patients with abdominal operations	Parallel groups double-blind
Hamburg , 1976 n=21/11 follow-up: 3 weeks	A+Dipyridamole,A1000 versus placebo	Elective orthopaedic surgery	
Frankfurt , 1981 <i>unpublished</i> n=25/14 follow-up:	A+Dip,A1320 versus placebo	patients with myocardial infarction	Parallel groups double-blind
dipyridamol + ASA vs placebo			
Denver-II , 1980 n=19/19 follow-up: 18 months	dipyridamole 100 mg a day and aspirin 1200 mg a day versus placebo	patients with recurring venous thromboembolism	Parallel groups double-blind
dipyridamol + aspirin vs placebo			
Encke IA , 1976 n=21/9	A990,A+Dip versus Placebo	-	double-blind
Encke IB , 1976 n=62/34	A1500,A990+Dip versus Placebo	-	double-blind

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q87>
- antithrombotics for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q92>
- antiplatelets drug for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q186>
- antiplatelets drug for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q461>
- antiplatelets drug for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q462>
- antiplatelets drug for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q463>
- antiplatelets drug for thrombosis prevention in elective orthopedic surgery at <http://www.trialresultscenter.org/go-Q464>

References

Chicago, 1982:

Green D, Rossi EC, Yao JS, Flinn WR, Spies SM Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole. Paraplegia 1982;20:227-34 [6813814]

Parodi I, 1973:

Parodi JC, Grandi A, Font E, Rotondaro D, Iorio J, Manrique J. El dipiridamol y el acido acetilsalicilico en la profilaxis de las trombosis venosas postoperatorias de los miembros inferiores Dia Med 1973;45:92-3.

Parodi II, 1973:

Parodi JC, Grandi A, Font E, Rotondaro D, Iorio J, Manrique J. El dipiridamol y el acido acetilsalicilico en la profilaxis de las trombosis venosas postoperatorias de los miembros inferiores Dia Med 1973;45:92-3.

Australian I, 1975:

O'Sullivan EF, Renney]T. Antiplatelet drugs in the prevention of postoperative deep vein thrombosis In: Proceedings of III congress of Interiational Societyfor Thrombosis andHaemnostasis (Washington). 1972:438.

Australian II, 1976:

Renney JT, O'Sullivan EF, Burke PF Prevention of postoperative deep vein thrombosis with dipyridamole and aspirin. Br Med J 1976;1:992-4 [773495]

Toulouse I, 1979:

Plante J, Boneu B, Vaysse C, Barret A, Gouzi M, Bierme R Dipyridamole-aspirin versus low doses of heparin in the prophylaxis of deep venous thrombosis in abdominal surgery. Thromb Res 1979;14:399-403 [442014]

Zekert-III, 1977:

Zekert F. Prophylaxe von phlebothrombosen und lungenembolien mit aggregationshemmemn In: Zekert F, ed. Thrombosen, Embolien und Aggregatonshemsnerin derChirurgie. Stuttgart: Schattauer, 1975:75-88.

Harjola DVT, 1982:

Harjola P, Meurala H, Frick AMH. Prevention of deep venous thrombosis and thrombo-embolism by dipyridamole and acetylsalicylic acid after revascularization arterial surgery *J Cardotzasc Surg* 1980;21:451-4.

Weiss, 1977:

Weiss V, Jekiel M, Ritschard J, Bouvier CA. Prevention of the thrombo-embolic disease post-operative by the anti-aggregants in gynecological surgery *Medicine et Hygiene (Geneve)* 1977;35:943-4.

Morris-B , 1977:

Morris GK, Mitchell JR Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. *Br Med J* 1977;1:535-7 [843794]

Lyon-I, 1975:

Dechavanne M, Ville D, Viala JJ, Kher A, Faivre J, Pousset MB, Dejour H Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. *Haemostasis* 1975;4:94-100 [1205340]

Morris-A , 1977:

Morris GK, Mitchell JR Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. *Br Med J* 1977;1:535-7 [843794]

Encke-II , 1976:

Encke A, Stock C, Dumke HO [Double-blind study for the prevention of postoperative thrombosis] *Chirurg* 1976;47:670-3 [1001131]

Hamburg, 1976:

Boehringer Ingelheim DVT nach Hirntumoroperationen *Boehringer Ingelheim*, 1976. (Internal report.)

Frankfurt, 1981:

unpublished

Boehringer Ingelheim. Asasantin DVT nach Myokardinfarkt *Bracknell Berkshire: Boehringer Ingelheim*, 1981. (Internal report.)

Denver-II , 1980:

Steele P Trial of dipyridamole-aspirin in recurring venous thrombosis. *Lancet* 1980;2:1328-9 [6109150]

Encke IA, 1976:

Encke A, Stock C, Dumke HO [Double-blind study for the prevention of postoperative thrombosis] *Chirurg* 1976;47:670-3 [1001131]

Schreiber U, Hartung B [Prevention of postoperative thromboembolism with micristin in general surgical patients (author's transl)] *Zentralbl Chir* 1979;104:1214-20 [543338]

Encke IB, 1976:

Encke A, Stock C, Dumke HO [Double-blind study for the prevention of postoperative thrombosis] *Chirurg* 1976;47:670-3 [1001131]

6 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
dipyridamol vs control			

continued...

Trial	Treatments	Patients	Trials design and methods
Atlanta (Sbar) , 1967 n=30/30 follow-up: 6 months	dipyridamole 150mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Wirecki , 1967 n=28/28 follow-up: 7 months	dipyridamole 150mg daily versus placebo	patients with angina pectoris	parallel groups double blind
Becker , 1967 n=14/13 follow-up: 5 months	dipyridamole 225mg daily versus placebo	-	parallel groups double-blind
dipyridamol vs placebo			
Kinsella , 1962 n=13/13 follow-up: 0.5 months	dipyridamole 37.5 mg and 100mg daily versus placebo	-	parallel groups double-blind
Leiberman , 1964 n=19/19 follow-up: >3 months	dipyridamole 100mg daily versus placebo	-	parallel groups double blind
Zion , 1961 n=14/14 follow-up: 0.5 months	Dipyridamole 37.5mg versus placebo	patients with angina pectoris	cross-over double-blind
Dewar , 1961 n=17/17 follow-up: 0.5 months	Dipyridamole 100mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Neumann , 1964 n=20/16 follow-up: 1.5 months	dipyridamole 150mg daily versus placebo	elderly with precordial pain	parallel groups double-blind
Foulds , 1960 n=24/24 follow-up: 1 months	Dipyridamole 200mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Igloe , 1970 n=26/22 follow-up: 2-7 months	Dipyridamole 200mg daily versus placebo	patients with angina pectoris	parallel groups double blind
dipyridamol + aspirin vs placebo			
PARIS , 1980 n=810/406 follow-up: 41 months (mean)	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and UK

continued...

Trial	Treatments	Patients	Trials design and methods
PARIS-II , 1986 n=1563/1565 follow-up: 23.4 months	Aspirin (330 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously	Parallel groups Double blind USA and UK
dipyridamol + aspirin vs aspirin			
PARIS , 1980 n=810/810 follow-up: 41 months	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Aspirin (324 mg) 3x/d	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and GB

More details and results :

- death and events prevention for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q450>

References

Atlanta (Sbar), 1967:

Sbar S, Schlant RC Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA 1967;201:865-7 [5340622]

Wirecki, 1967:

Wirecki M Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis 1967;20:139-45 [5336520]

Becker, 1967:

Becker MC. Angina pectoris: A double blind study with dipyridamole Journal of the Newark Beth Israel Hospital 1967;18:88-94

Kinsella, 1962:

KINSELLA D, TROUP W, MCGREGOR M Studies with a new coronary vasodilator drug: persantin. Am Heart J 1962;63:146-51 [14456202]

Leiberman, 1964:

LEIBERMAN A, GUGLIELMELLI S PERSANTIN- A DOUBLE BLIND STUDY. Angiology 1964;15:290-2 [14170587]

Zion, 1961:

ZION MM, BRADLOW BA A controlled clinical trial of 'persantin' (R A 8) in angina pectoris. S Afr Med J 1961;35:11-3 [13788617]

Dewar, 1961:

DEWAR HA, HORLER AR A clinical trial of Persantin and Crodimyl in the treatment of angina of effort. Scott Med J 1961;6:149-52 [13722387]

Neumann, 1964:

NEUMANN M, LUISADA AA EFFECT OF RAPID AND SLOW-ACTING "CORONARY" DRUGS ON PRECORDIAL PAIN OF THE AGED. Am J Med Sci 1964;247:156-63 [14124704]

Foulds, 1960:

FOULDS T, MACKINNON J Controlled double-blind trial of "persantin" in treatment of angina pectoris. Br Med J 1960;2:835 [13824151]

Igloe, 1970:

Igloe MC Treatment of angina pectoris with dipyridamole: a double-blind study. J Am Geriatr Soc 1970;18:233-41 [4984849]

PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

PARIS-II, 1986:

Klimt CR, Knatterud GL, Stamler J, Meier P, Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7:251-69 [2868029]

PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

7 CABG surgery

Trial	Treatments	Patients	Trials design and methods
aspirin + dipyridamol vs control			
Pantely , 1979 n=18/30 follow-up: 6m	aspirin 325 mg three times a day + dipyridamole 75 mg three times a day versus control	patients undergoing aortocoronary saphenous-vein bypass-graft surgery	open
Brussels , 1987 n=24/25 follow-up: 12m	-	-	
Czech , 1986 n=47/46 follow-up: 12m	aspirin 1000 + dipyridamol 225 versus control (no medication)	Patients with aortocoronary bypasses with intraoperative blood flow rates of 40 ml/min or less	open
Des Moines , 1980 n=60/54 follow-up: 12m	-	-	
dipyridamol vs control			
Toronto dipyridamole , 1987 n=20/20 follow-up: 48h	dipyridamol 400 versus control	patients undergoing elective coronary artery bypass grafting	
aspirin + dipyridamol vs placebo			
GESIC (aspirin+dipyridamol) , 1990 n=368/371 follow-up: 28d	aspirin 50 mg + dipyridamole 75mg 3 times daily versus placebo	patients undergoing CABG	Parallel groups double blind Spain

continued...

Trial	Treatments	Patients	Trials design and methods
Brooks , 1985 n=160/160 follow-up: 12m	aspirin 990 mg and dipyridamole 225 mg daily versus placebo	patients undergoing coronary bypass grafting	double blind
Mayo-A , 1984 n=202/205 follow-up: 12m	aspirin 975 + dipyridamol 225 versus placebo	patients undergoing coronary bypass grafting	double blind
Wadsworth , 1985 n=96/102 follow-up: 12m	aspirin 975 mg/d + dipyridamol 225 mg/d, aspirin 975 mg/d versus placebo	coronary bypass patients	double blind
Basel , 1989 n=62/63 follow-up: 9m	aspirin 50 + dipyridamol 400 versus placebo	patients who had aortocoronary vein bypass surgery	double blind
Leeds-B , 1985 n=61/64 follow-up: 6m	aspirin 990 + dipyridamol 225 (W) versus placebo	patients undergoing aorta-coronary bypass grafting for disabling angina	double blind
Thaulow , 1987 n=34/35 follow-up: 3m	aspirin 975 + dipyridamol 225 versus placebo	Patients scheduled to receive at least three aortocoronary venous bypass grafts	double blind
dipyridamol vs placebo			
Ekestrom , 1990 n=174/186 follow-up: 12m	dipyridamol 100 mg orally q.i.d. versus placebo	patients undergoing coronary bypass surgery	double blind

More details and results :

- antiplatelets drug for CABG surgery in all type of patients at <http://www.trialresultscenter.org/go-Q225>

References

Pantely, 1979:

Pantely GA, Goodnight SH Jr, Rahimtoola SH, Harlan BJ, DeMots H, Calvin L, Rsch J Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. N Engl J Med 1979;301:962-6 [386118]

Brussels, 1987:

Lavenne-Pardonge E, Col-de Beys C, Dion R, Ponlot R, Moriau M.A Effect of antiaggregant on occlusion of saphenous graft coronary bypass Thromb Haemost 1987;58:547 (Abstract 2024)

Czech, 1986:

Pirk J, Vojcek J, Kovc J, Fabin J, Firt P Improved patency of the aortocoronary bypass by antithrombotic drugs. Ann Thorac Surg 1986;42:312-4 [3489445]

Des Moines, 1980:

Klotz L Antiplatelet and anticoagulant therapy after coronary bypass. *N Engl J Med* 1980;302:866 [6965764]

Toronto dipyridamole, 1987:

Teoh KH, Christakis GT, Weisel RD, Madonik MM, Ivanov J, Wong PY, Mee AV, Levitt D, Benak A, Reilly P Blood conservation with membrane oxygenators and dipyridamole. *Ann Thorac Surg* 1987;44:40-7 [3300583]

GESIC (aspirin+dipyridamol), 1990:

Sanz G, Pajarn A, Alegria E, Coello I, Cardona M, Fournier JA, Gmez-Recio M, Ruano J, Hidalgo R, Medina A *Circulation* 1990;82:765-73 [2203555]

Brooks, 1985:

Brooks N, Wright J, Sturridge M, Pepper J, Magee P, Walesby R, Layton C, Honey M, Balcon R Randomised placebo controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion. *Br Heart J* 1985;53:201-7 [3881108]

Mayo-A, 1984:

Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR Jr, Bardsley WT, Pluth JR, Wallace RB, Puga FJ Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. *N Engl J Med* 1984;310:209-14 [6361561]

Wadsworth, 1985:

Brown BG, Cukingnan RA, DeRouen T, Goede LV, Wong M, Fee HJ, Roth JA, Carey JS Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. *Circulation* 1985;72:138-46 [3874009]

Basel, 1989:

Pfisterer M, Burkart F, Jockers G, Meyer B, Regenass S, Burckhardt D, Schmitt HE, Mller-Brand J, Skarvan K, Stulz P Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. *Lancet* 1989;2:1-7 [2567792]

Leeds-B, 1985:

Rajah SM, Salter MC, Donaldson DR, Subba Rao R, Boyle RM, Partridge JB, Watson DA Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. A double-blind, placebo-controlled, randomized trial. *J Thorac Cardiovasc Surg* 1985;90:373-7 [3897722]

Thaulow, 1987:

Thaulow E, Frysaker T, Dale J, Vatne K Failure of combined acetylsalicylic acid and dipyridamole to prevent occlusion of aortocoronary venous bypass graft. *Scand J Thorac Cardiovasc Surg* 1987;21:215-20 [3501902]

Ekestrom, 1990:

Ekestrm SA, Gunnes S, Brodin UB Effect of dipyridamole (Persantin) on blood flow and patency of aortocoronary vein bypass grafts. *Scand J Thorac Cardiovasc Surg* 1990;24:191-6 [2293357]

8 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
aspirin + dipyridamol vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
Hess (2) , 1985 n=80/80 follow-up:	Aspirine Dipyridamole 330 mg / j 225 mg / j versus Placebo	patients with occlusive arterial disease in the lower extremities	Parallel groups double blind
Schoop (2) , 1983 n=100/100 follow-up:	Aspirine Dipyridamole 990 mg / j 225 mg /j versus Placebo	AOMI stade non precis	Parallel groups double blind
VA study , 1986 n=110/121 follow-up: 46 months	Aspirine + Dipyridamole 975 mg / j 225 mg /j versus Placebo	non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene	Parallel groups double blind

More details and results :

- antiplatelets drug for peripheral vascular diseases in all type of patient at <http://www.trialresultscenter.org/go-Q278>

References

Hess (2), 1985:

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Hess H, Mietaschk A, Deichsel G Lancet 1985 Feb 23;1:415-9 [2857803]

Schoop (2), 1983:

W Schoop, H Levy. prevention of peripheral arterial occlusive disease with antiaggregants. Thromb Haemost 1983, 30: 137.

VA study, 1986:

Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Colwell JA, Bingham SF, Abaira C, Anderson JW, Comstock JP, Kwaan HC, Nuttall F Diabetes Care 1986 Mar-Apr;9:140-8 [3516608]

9 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
aspirin + dipyridamol vs placebo			
Schwartz (Toronto) , 1988 n=187/189 follow-up: 6m	aspirin 990 + D225 (H) versus placebo	-	Parallel groups double blind Canada

continued...

Trial	Treatments	Patients	Trials design and methods
White (aspirin+dipyridamol) , 1991 n=245/254 follow-up: 6m	-	-	Parallel groups
Nye (Dunedin) , 1990 n=35/37 follow-up: 12m	aspirin 300 + D225 versus placebo	-	Parallel groups NA
Mayo-PTCA , 1989 n=102/105 follow-up: 48h	-	-	Parallel groups

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>

References

Schwartz (Toronto), 1988:

Schwartz L, Bourassa MG, Lesprance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-9 [2967433]

White (aspirin+dipyridamol), 1991:

White CW, Chaitman B, Knudtson ML, Chisholm RJ, and the Ticlopidine Study Group. Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis: results from the ticlopidine trial Coronary Artery Dis 1991;2:757-67

Nye (Dunedin), 1990:

Nye ER, Ablett MB, Robertson MC, Ilsley CD, Sutherland WH Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. Aust N Z J Med 1990;20:549-52 [2222347]

Mayo-PTCA, 1989:

Chesebro JH, Webster MW, Reeder GS, Mock MB, Grill DE, Bailey KR, et al. Coronary angioplasty: antiplatelet therapy reduces acute complications but not restenosis Circulation 1989;80 (suppl II):II-64 (Abstract 0257)

Entry terms: dipyridamole monoacetate, dipyridamol monoacetate,